About mesoblast ltd - MESO
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
MESO At a Glance
Mesoblast Ltd.
55 Collins Street
Melbourne, Victoria (VIC) 3000
| Phone | 61-3-9639-6036 | Revenue | 17.17M | |
| Industry | Biotechnology | Net Income | -101,968,355.96 | |
| Sector | Health Technology | 2025 Sales Growth | 189.835% | |
| Fiscal Year-end | 06 / 2026 | Employees | 81 | |
| View SEC Filings |
MESO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 76.609 |
| Price to Book Ratio | 2.333 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -22.878 |
| Enterprise Value to Sales | 74.664 |
| Total Debt to Enterprise Value | 0.10 |
MESO Efficiency
| Revenue/Employee | 211,960.036 |
| Income Per Employee | -1,258,868.592 |
| Receivables Turnover | 1.155 |
| Total Asset Turnover | 0.024 |
MESO Liquidity
| Current Ratio | 1.991 |
| Quick Ratio | 1.774 |
| Cash Ratio | 1.574 |
MESO Profitability
| Gross Margin | 32.957 |
| Operating Margin | -363.577 |
| Pretax Margin | -592.476 |
| Net Margin | -593.918 |
| Return on Assets | -14.027 |
| Return on Equity | -18.922 |
| Return on Total Capital | -14.053 |
| Return on Invested Capital | -16.295 |
MESO Capital Structure
| Total Debt to Total Equity | 21.451 |
| Total Debt to Total Capital | 17.662 |
| Total Debt to Total Assets | 16.332 |
| Long-Term Debt to Equity | 11.938 |
| Long-Term Debt to Total Capital | 9.829 |